Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.76 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.48 |
| ▸ | KLK1 | P06870 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 4/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | PDE9A | O76083 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468889 | 0.93 | AR (0.86) | ARCYP19A1CYP11B1CYP11B2PDE9A | |
| SCHEMBL24414502 | 0.89 | AR (0.80) | ARCYP19A1CYP11B1CYP11B2PDE9A | |
| SCHEMBL24411088 | 0.86 | AR (0.76) | ARKLKB1KLK1CYP19A1CYP11B1 | |
| SCHEMBL24411064 | 0.86 | AR (0.76) | ARCYP19A1CYP11B1CYP11B2PDE9A | |
| SCHEMBL20051214 | 0.84 | AR (0.72) | ARLOXL2KLKB1KLK1CYP19A1 | |
| SCHEMBL20051520 | 0.84 | AR (0.72) | ARCYP19A1 | |
| SCHEMBL6465872 | 0.84 | AR (0.76) | ARCYP19A1CYP11B1CYP11B2PDE9A | |
| SCHEMBL6468062 | 0.82 | AR (1.00) | ARPDE9APDE1C | |
| SCHEMBL6464451 | 0.82 | AR (0.80) | ARCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6889022 | 0.81 | AR (0.68) | ARLOXL2KLKB1KLK1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886854-A1 | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Nuvation Bio Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11034669-B2 | Pyrrole and pyrazole compounds and methods of use thereof | NUVATION BIO INC. (BM) | 2021-06-15 | — | — | US | disclosed |
| US-11034669-B2 | Pyrrole and pyrazole compounds and methods of use thereof | NUVATION BIO INC. (BM) | 2021-06-15 | — | — | US | disclosed |
| US-20200239433-A1 | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-30 | — | — | US | disclosed |
| US-20200239433-A1 | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-30 | — | — | US | disclosed |
| WO-2020113094-A1 | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF | NUVATION BIO INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239433-A1 | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF | NCOA3, NCOA1, NR3C1 | AR 15/4885LOXL2 4433/4885KLKB1 1188/4885 |
| US-11034669-B2 | Pyrrole and pyrazole compounds and methods of use thereof | NCOA3, NCOA1, NR3C1 | AR 15/4885LOXL2 4433/4885KLKB1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.